Oct. 23 at 11:23 AM
$CGTX The two P3 ALZ studies will run well over
$100 million, possibly closer to
$200MM. If they pan out well you can expect a SP many times today's pittance. BUT, you can also expect further dilution. Easily by 50%. Expect it and weigh against the massive market and profits for their ALZ treatment.